Press Releases

 
Press Releases
  Date Title View
Jun 11, 2016
BERKELEY, CA -- (Marketwired) -- 06/11/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced preliminary results from a pivotal Phase 3 trial demonstrating that HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] provided a significantly higher rate of seroprotection than Engerix-B®, an approved hepatitis B vaccine, in a...
May 18, 2016
BERKELEY, CA -- (Marketwired) -- 05/18/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present at two upcoming investor conferences. Information relating to the two presentations follows: 2016 UBS Global Healthcare Conference Michael Ostrach, Dynavax's senior vice pre...
May 9, 2016
BERKELEY, CA -- (Marketwired) -- 05/09/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2016. The Company had $166.8 million in cash, cash equivalents and marketable securities as of March 31, 2016, compared to $196.1 million at December 31, 2015. The net lo...
Apr 27, 2016
BERKELEY, CA -- (Marketwired) -- 04/27/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of the Biologics License Application (BLA) for HEPLISAV-B™, Dynavax's investigational vaccine for immunization of adults agains...
Apr 18, 2016
BERKELEY, CA -- (Marketwired) -- 04/18/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced encouraging additional data from Part 1 of a Phase 1/2 study (LYM-01) evaluating the company's lead immunotherapy product candidate, SD-101, in combination with low-dose radiation in lymphoma patients. The data were presented at the A...
Apr 18, 2016
BERKELEY, CA -- (Marketwired) -- 04/18/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced results from HBV-23, a pivotal Phase 3 trial that provides head-to-head safety and immunogenicity data comparing its investigational adult hepatitis B vaccine, HEPLISAV-B, with the leading vaccine, Engerix-B, in adults 18 to 70 years ...
Apr 4, 2016
BERKELEY, CA -- (Marketwired) -- 04/04/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present HEPLISAV-B pivotal Phase 3 data at the National Foundation for Infectious Diseases' 19th Annual Conference on Vaccine Research (ACVR). The Conference will take place in Baltimore, Maryland from April 18th throu...
Mar 30, 2016
BERKELEY, CA -- (Marketwired) -- 03/30/16 -- ┬áDynavax Technologies Corporation (NASDAQ: DVAX) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for HEPLISAV-B™, the company's vaccine candidate for immunization against hepatitis B infection in adults 18 years...
Mar 17, 2016
BERKELEY, CA -- (Marketwired) -- 03/17/16 --  Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present data at the American Association for Cancer Research Annual Meeting next month in New Orleans, Louisiana. The details for the poster presentations are as follows: Date and Time: Monday, April...
Mar 8, 2016
BERKELEY, CA -- (Marketwired) -- 03/08/16 --  Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2015. The Company had $196.1 million in cash, cash equivalents and marketable securities as of December 31, 2015. Total revenues for the year ende...
FirstPrevious
3
...
NextLast
= add release to Briefcase